GlassScriptPhysician profile
Joseph E Pruitt
NPI 1649241845
$2,322.51
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $762 · 2023: $1,134 · 2024: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $467.43 | 2021-2023 | Aveir, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $408.20 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $327.35 | 2022-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $158.77 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $146.86 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $135.39 | 2023 | Farxiga, Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.62 | 2023 | Xifaxan |
| Amgen INC. | $110.06 | 2022-2023 | Repatha |
| Boston Scientific Corporation | $106.63 | 2022-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.77 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $59.30 | 2022-2023 | |
| Novo Nordisk INC | $44.72 | 2022-2023 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $32.53 | 2023-2024 | Nexletol |
| Pfizer INC. | $29.47 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.85 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $25.02 | 2022 | |
| Irhythm Technologies, INC. | $23.24 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.30 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.